Related Experiment Video
Updated: Aug 8, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Strategies towards a longer acting factor VIII
1Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, USA.
Summary
Advancements in biotechnology have improved hemophilia care, but barriers to effective prophylaxis persist. New long-acting factor VIII (FVIII) therapies aim to overcome these challenges for better patient outcomes.
Area of Science:
- Biotechnology and Hematology
Background:
- Significant progress in hemophilia care, including reduced mortality and improved quality of life, has been achieved through advancements in biotechnology and comprehensive care models.
- Biotechnology innovations such as improved pathogen screening, viral inactivation, and recombinant clotting factors have been pivotal.
- Despite these advances, challenges remain in the widespread adoption and adherence to effective prophylactic therapies for hemophilia.
Purpose of the Study:
- To explore the development and potential of long-acting biological therapeutics for hemophilia.
- To discuss strategies for overcoming barriers to prophylactic therapy adherence.
- To evaluate novel approaches in modifying factor VIII (FVIII) for enhanced therapeutic efficacy.
Main Methods:
- Application of strategies successful in other therapeutic proteins to factor VIII (FVIII).
- Modifications include PEGylation (polyethylene glycol) and polysialic acid conjugation.
- Alternative formulations such as PEG-modified liposomes are being investigated.
- Targeted modifications of FVIII based on structure-function insights to prolong activity and reduce clearance.
Main Results:
- Long-acting biological therapeutics represent an incremental advancement in hemophilia treatment.
- Novel modifications aim to increase the in vivo half-life and cofactor activity of FVIII.
- These approaches hold promise for improving adherence and effectiveness of prophylactic treatment.
Conclusions:
- Biotechnology continues to drive innovation in hemophilia management.
- Long-acting FVIII formulations offer a potential solution to existing therapeutic barriers.
- Further research is needed to fully assess the advantages and disadvantages of these emerging therapies.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...